Commercialization strategies of biotechnology companies
Thesis (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, 1999.
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | eng |
| Published: |
Massachusetts Institute of Technology
2010
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1721.1/57763 |
| _version_ | 1811083510415360000 |
|---|---|
| author | Saghir, Mouris |
| author2 | Scott Stern. |
| author_facet | Scott Stern. Saghir, Mouris |
| author_sort | Saghir, Mouris |
| collection | MIT |
| description | Thesis (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, 1999. |
| first_indexed | 2024-09-23T12:34:13Z |
| format | Thesis |
| id | mit-1721.1/57763 |
| institution | Massachusetts Institute of Technology |
| language | eng |
| last_indexed | 2024-09-23T12:34:13Z |
| publishDate | 2010 |
| publisher | Massachusetts Institute of Technology |
| record_format | dspace |
| spelling | mit-1721.1/577632019-04-13T00:05:33Z Commercialization strategies of biotechnology companies Commercialization strategies in the biotechnology industry Saghir, Mouris Scott Stern. Sloan School of Management. Sloan School of Management. Sloan School of Management. Thesis (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, 1999. Includes bibliographical references (leaves 49-50). In the biotechnology industry today, there are many business models for project commercialization. These models range from independent vertical integration to certain forms of collaboration with pharmaceutical companies to complete acquisitions of projects by the big pharmaceutical companies. In this thesis, we wanted to study commercialization strategies of several biotechnology companies. We wanted to investigate the rational for commercialization decisions and the consequence of these decisions on biotechnology firms'. Thus, we conducted interviews with either founders or senior managers of business development of nine biotechnology firms to address these issues. Our results demonstrate that biotechnology firms reluctantly enter partnership agreements with pharmaceutical companies. In addition, there are delays in the negotiation process before agreements are reached, which can have negative impact on biotechnology firms. Furthermore, concentration on core competencies and the presence of champions at the pharmaceutical partners are two essential elements of successful commercialization for biotechnology firms. by Mouris Saghir. S.M. 2010-08-31T14:28:03Z 2010-08-31T14:28:03Z 1999 1999 Thesis http://hdl.handle.net/1721.1/57763 48193186 eng M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 67 leaves application/pdf Massachusetts Institute of Technology |
| spellingShingle | Sloan School of Management. Saghir, Mouris Commercialization strategies of biotechnology companies |
| title | Commercialization strategies of biotechnology companies |
| title_full | Commercialization strategies of biotechnology companies |
| title_fullStr | Commercialization strategies of biotechnology companies |
| title_full_unstemmed | Commercialization strategies of biotechnology companies |
| title_short | Commercialization strategies of biotechnology companies |
| title_sort | commercialization strategies of biotechnology companies |
| topic | Sloan School of Management. |
| url | http://hdl.handle.net/1721.1/57763 |
| work_keys_str_mv | AT saghirmouris commercializationstrategiesofbiotechnologycompanies AT saghirmouris commercializationstrategiesinthebiotechnologyindustry |